Clinical Trial: Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region

U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07370207) titled 'Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region' on Jan. 19.

Brief Summary: This study is a randomized, open-label, multicenter phase 2 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with HBeAg-negative CHB treated with NAs.

Study Start Date: Feb. 02

Study Type: INTERVENTIONAL

Condition: Hepatitis B, Chronic

Intervention: DRUG: AHB-137

Subcutaneous injection

Recruitment Status: NOT_YET_RECRUITING

Sponsor: AusperBio Therapeutics Inc.

Disclaimer: Curated by HT Syndication....